Middle East and Africa anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (South Africa, Rest of Middle East And Africa).
Some of the major factors contributing to the growth of the Middle East and Africa anticoagulation therapy market:

? Increase awareness about treatment of venous thromboembolism and pulmonary embolism
? Increasing number of surgeries

Market Players

The key market players for the Middle East and Africa anticoagulation therapy market are listed below:

? Hikma Pharmaceuticals PLC
? Mylan N.V.
? Teva Pharmaceutical Industries Ltd.
? Novartis AG
? Eisai Co., Ltd.
? Pfizer Inc.
? Sanofi
? F. Hoffmann-La Roche Ltd
? Fresenius Kabi AG
? Aspen Holdings
? Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
? Cipla Inc
? Johnson & Johnson Services, Inc.
? Bayer AG
? Boehringer Ingelheim International GmbH
? Bristol-Myers Squibb Company
? DAIICHI SANKYO COMPANY, LIMITED
? Eagle Pharmaceuticals, Inc
? Endo Pharmaceuticals Inc
? Mitsubishi Tanabe Pharma Corporation
? Portola Pharmaceuticals, Inc.
? Taro Pharmaceutical Industries Ltd.